CIK 0001601830
- Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464099738
- Phone
- +1 385-269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $701,222
- in 5 filings, $701K under 10b5-1 plans
Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-09-26 | Marriott Tina President and COO | Sale 10b5-1 | −6,000 | $7.00 | $42K | 521,138 |
| 2024-09-26 | Marriott Tina President and COO | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −0 | 458,000 | ||
| 2024-09-17 | Borgeson Blake Director | Sale 10b5-1 | −11,447 | $6.84 | $78K | 7,109,875 |
| 2024-09-11 | Secora Michael Chief Financial Officer | Exercise or conversion 10b5-1 | +39,375 | $2.22 | $87K | 1,417,131 |
| 2024-09-11 | Secora Michael Chief Financial Officer | Sale 10b5-1 | −15,000 | $6.32 | $95K | 1,402,131 |
| 2024-09-11 | Secora Michael Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −39,375 | 495,135 | ||
| 2024-09-10 | Secora Michael Chief Financial Officer | Exercise or conversion 10b5-1 | +39,375 | $2.22 | $87K | 1,392,756 |
| 2024-09-10 | Secora Michael Chief Financial Officer | Sale 10b5-1 | −15,000 | $6.17 | $92K | 1,377,756 |
| 2024-09-10 | Secora Michael Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −39,375 | 534,510 | ||
| 2024-09-05 | Gibson Christopher Chief Executive Officer | Conversion 10b5-1 | +20,000 | 782,656 | ||
| 2024-09-05 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −20,000 | $6.14 | $123K | 762,656 |
| 2024-09-05 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock 10b5-1 | −20,000 | 6,136,700 | ||
| 2024-09-04 | Gibson Christopher Chief Executive Officer | Conversion 10b5-1 | +20,000 | 782,656 | ||
| 2024-09-04 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −20,000 | $6.04 | $121K | 762,656 |
| 2024-09-04 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock 10b5-1 | −20,000 | 6,156,700 | ||
| 2024-09-03 | Borgeson Blake Director | Sale 10b5-1 | −11,447 | $6.27 | $72K | 7,121,322 |
| 2024-08-30 | Gibson Christopher Chief Executive Officer | Exercise or conversion | +5,000 | $2.48 | $12K | 762,656 |
| 2024-08-30 | Gibson Christopher Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy) | −5,000 | 282,500 | ||
| 2024-08-29 | Marriott Tina President and COO | Exercise or conversion 10b5-1 | +6,000 | $1.06 | $6K | 527,138 |
| 2024-08-29 | Marriott Tina President and COO | Sale 10b5-1 | −6,000 | $7.56 | $45K | 521,138 |
Page 15 of 41 · 805 trades